Eli Lilly Gains Momentum from Weight-Loss Drug Demand: Gary Black Finds Valuation Attractive

Eli Lilly continues to benefit from strong consumer interest in weight-loss drugs. Gary Black, managing partner of Future Fund LLC, highlighted the company's robust position in this sector, stating that Eli Lilly's current valuation remains attractive. Black noted that investors' 'love affair' with weight-loss medications supports the company's growth potential. In a post on social media platform X, Black emphasized Eli Lilly's leadership in the weight-loss drug market. He pointed out that products like Mounjaro and Zepbound are driving demand, positively impacting the company's revenues. 'Consumers show great loyalty to these drugs, and Eli Lilly is one of the biggest beneficiaries of this trend,' Black said. The analyst expects Eli Lilly's earnings per share growth to remain strong in the coming years. Black stated that the company's R&D spending and new product launches will support this growth. He also argued that Eli Lilly's current market value is still reasonable given its future cash flows. Black's comments reflect optimism that Eli Lilly's dominance in the weight-loss drug market will continue. The company is working to increase production capacity and develop new treatment options to maintain its competitive edge. Investors believe Eli Lilly's strategy will create long-term value. This is not investment advice.